Is Cue Biopharma going out of business?

Cue Biopharma, Inc. (CUE) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Cue Biopharma, Inc. (CUE) scores 32 out of 100 on fundamentals, Speculative / Volatile, based on SEC filing data.

Leading signal: Interest coverage: -986.7x

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-06-30, based on $17.4M of cash and short-term investments against $73.0M of annual burn.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

6.5% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Debt / Equity: -6.20x (Net Cash)
• Interest coverage: -986.7x
• Cash Runway (years): 0.24y
• Revenue CAGR (3Y): 180.46%
• Revenue growth YoY: 166.66% (YoY) - Growth from a low base; sustainability uncertain.
• Return on Assets: -534.43%
• Revenue per Asset Efficiency: 39.30% QoQ (Strong monetization)
• FCF margin: -193.85% (Inv. Mode)
• Cash Burn Deceleration: -161.43% QoQ improvement (Worsening)
• Working Capital Efficiency: 44.67x (Well-funded)
• Revenue Quality: Quality concerns (DSO +29d, Rev +167%)
• Price / Sales: 5.9x (see Valuation)

Read from filings through 2026-08-14.

Price as of 2026-09-07.